Segment, Geographic and Other Revenue Information (Tables)

12 Months Ended

Dec. 31, 2011

Schedule of Selected Income Statement Information by Segment

Selected income statement information follows:


(MILLIONS OF DOLLARS)	REVENUES		R&D EXPENSES			EARNINGS^(a)			DEPRECIATION & AMORTIZATION^(b)
YEAR ENDED DECEMBER 31, 2011^(c)
Primary Care		$22,670		$1,307			$15,001			$ 247
Specialty Care and Oncology		16,568		1,561			10,789			419
Established Products and Emerging Markets		18,509		441			9,417			422
Animal Health and Consumer Healthcare		7,241		425			2,020			232
Total reportable segments		64,988		3,734			37,227			1,320
Nutrition and other business activities^(d)		2,437		3,378			(2,793	)		230
Reconciling Items:
Corporate^(e)		—		1,309			(7,430	)		541
Purchase accounting adjustments^(f)		—		(2	)		(6,801	)		5,565
Acquisition-related costs^(g)		—		23			(1,983	)		624
Certain significant items^(h)		—		656			(4,354	)		615
Other unallocated⁽ⁱ⁾		—		14			(1,104	)		131
		$67,425		$9,112			$12,762			$9,026

YEAR ENDED DECEMBER 31, 2010
Primary Care		$23,328		$1,473			$15,773			$201
Specialty Care and Oncology		16,435		1,624			10,571			432
Established Products and Emerging Markets		18,760		452			10,100			418
Animal Health and Consumer Healthcare		6,347		428			1,569			197
Total reportable segments		64,870		3,977			38,013			1,248
Nutrition and other business activities^(d)		2,187		3,743			(3,263	)		242
Reconciling Items:
Corporate^(e)		—		1,567			(7,990	)		619
Purchase accounting adjustments^(f)		—		26			(8,257	)		5,477
Acquisition-related costs^(g)		—		34			(3,989	)		788
Certain significant items^(h)		—		18			(3,964	)		—
Other unallocated⁽ⁱ⁾		—		27			(1,268	)		113
		$67,057		$9,392			$9,282			$8,487

YEAR ENDED DECEMBER 31, 2009^(c)
Primary Care		$22,576		$1,407			$15,100			$130
Specialty Care and Oncology		8,925		1,060			4,661			269
Established Products and Emerging Markets		13,947		392			6,955			360
Animal Health and Consumer Healthcare		3,258		297			812			142
Total reportable segments		48,706		3,156			27,528			901
Nutrition and other business activities^(d)		563		2,706			(2,751	)		181
Reconciling Items:
Corporate^(e)		—		1,296			(4,657	)		526
Purchase accounting adjustments^(f)		—		37			(3,787	)		2,799
Acquisition-related costs^(g)		—		13			(4,025	)		241
Certain significant items^(h)		—		56			(1,511	)		—
Other unallocated⁽ⁱ⁾		—		560			(123	)		109
		$49,269		$7,824			$10,674			$4,757

^(a)	Income from continuing operations before provision for taxes on income.

^(b)	Certain production facilities are shared. Depreciation is allocated based on estimates of physical production.

^(c)	For 2011, includes King commencing on the acquisition date of January 31, 2011. For 2009, includes Wyeth commencing on the acquisition date of October 15, 2009.

^(d)

Other business activities includes the revenues and operating results of Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales operation, and the research and development costs managed by our Worldwide Research and Development organization and our Pfizer Medical organization.

^(e)

Corporate for R&D expenses includes, among other things, administration expenses and compensation expenses associated with our research and development activities and for Earnings includes, among other things, administration expenses, interest income/(expense), certain compensation and other costs not charged to our operating segments.

^(f)	Purchase accounting adjustments include certain charges related to the fair value adjustments to inventory, intangible assets and property, plant and equipment.

^(g)

Acquisition-related costs can include costs associated with acquiring, integrating and restructuring newly acquired businesses, such as transaction costs, integration costs, restructuring charges and additional depreciation associated with asset restructuring (see Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives for additional information).

^(h)

Certain significant items are substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include restructuring charges and implementation costs associated with our cost-reduction and productivity initiatives that are not associated with an acquisition, the impact of certain tax and/or legal settlements and certain asset impairments.

⁽ⁱ⁾

Includes overhead expenses associated with our manufacturing and commercial operations not directly attributable to an operating segment. In 2009, R&D expenses include approximately $550 million of Wyeth R&D expenses and Earnings include approximately $900 million of Wyeth earnings and $290 million of operating expenses incurred in Japan associated with our three biopharmaceutical operating segments, where allocation among the segments is not practicable.

Schedule of Revenues by Geographic Region

Revenues by geographic region follow:



	YEAR ENDED DECEMBER 31,
(MILLIONS OF DOLLARS)	2011		2010		2009
Revenues^(a)
United States	$	26,933	$	28,855	$	21,540
Developed Europe^(b)		16,297		16,345		12,586
Developed Rest of World^(c)		11,091		10,008		8,097
Emerging Markets^(d)		13,104		11,849		7,046
Consolidated	$	67,425	$	67,057	$	49,269

^(a)	For 2011, includes King commencing on the acquisition date of January 31, 2011. For 2009, includes Wyeth commencing on the acquisition date of October 15, 2009.

^(b)	Developed Europe region includes the following markets: Western Europe, Finland and the Scandinavian countries. Euro revenues were approximately $12 billion for each of 2011 and 2010 and $10 billion for 2009.

^(c⁾	Developed Rest of World region includes the following markets: Australia, Canada, Japan, New Zealand, and South Korea.

^(d)	Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Middle East, Africa, Central and Eastern Europe and Turkey.

Schedule of Long-Lived Assets by Geographic Region

Long-lived assets by geographic region follow:



	AS OF DECEMBER 31,
(MILLIONS OF DOLLARS)	2011		2010
Property, plant and equipment, net
United States		$ 7,893		$ 8,537
Developed Europe^(a)		6,023		7,159
Developed Rest of World^(b)		904		854
Emerging Markets^(c)		2,118		2,095
Consolidated		$16,938		$18,645

^(a)	Developed Europe region includes the following markets: Western Europe, Finland and the Scandinavian countries.

^(b⁾	Developed Rest of World region includes the following markets: Australia, Canada, Japan, New Zealand, and South Korea.

^(c)	Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Middle East, Africa, Central and Eastern Europe and Turkey.

Schedule of Significant Product Revenues

Significant product revenues follow:



	YEAR ENDED DECEMBER 31,
(MILLIONS OF DOLLARS)	2011		2010		2009

Revenues from biopharmaceutical products^(a):
Lipitor^(b)		$9,577		$10,733		$11,434
Lyrica		3,693		3,063		2,840
Prevnar 13/Prevenar 13^(c)		3,657		2,416		—
Enbrel (Outside the U.S. and Canada)^(c)		3,666		3,274		378
Celebrex		2,523		2,374		2,383
Viagra		1,981		1,928		1,892
Norvasc		1,445		1,506		1,973
Zyvox		1,283		1,176		1,141
Xalatan/Xalacom		1,250		1,749		1,737
Sutent		1,187		1,066		964
Geodon/Zeldox		1,022		1,027		1,002
Premarin family^(c)		1,013		1,040		213
Genotropin		889		885		887
Detrol/Detrol LA		883		1,013		1,154
Vfend		747		825		798
Chantix/Champix		720		755		700
BeneFIX^(c)		693		643		98
Effexor^(c)		678		1,718		520
Zosyn/Tazocin^(c)		636		952		184
Pristiq^(c)		577		466		82
Zoloft		573		532		516
Caduet		538		527		548
Revatio		535		481		450
Medrol		510		455		457
ReFacto AF/Xyntha^(c)		506		404		47
Prevnar/Prevenar (7-valent)^(c)		488		1,253		287
Zithromax/Zmax		453		415		430
Aricept^(d)		450		454		435
Fragmin		382		341		359
Cardura		380		413		457
Rapamune^(c)		372		388		57
Aromasin		361		483		483
BMP2^(c)		340		400		81
Relpax		341		323		326
Xanax XR		306		307		318
Tygacil^(c)		298		324		54
Neurontin		289		322		327
Diflucan		265		278		281
Arthrotec		242		250		270
Unasyn		231		244		245
Sulperazon		218		213		204
Skelaxin^(e)		203		—		—
Inspra		195		157		130
Dalacin/Cleocin		192		214		241
Methotrexate		191		164		21
Toviaz		187		137		59
Somavert		183		157		147
Alliance revenues^(f)		3,630		4,084		2,925
All other biopharmaceutical products^(g)		6,768		6,194		4,913

Total revenues from biopharmaceutical products		57,747		58,523		45,448

Revenues from other products^(a):
Animal Health^(g)		4,184		3,575		2,764
Consumer Healthcare^(c)		3,057		2,772		494
Nutrition^(c)		2,138		1,867		191
Pfizer CentreSource		299		320		372

Total revenues^(a)		$67,425		$67,057		$49,269

^(a)	For 2011, includes King commencing on the acquisition date of January 31, 2011. For 2009, includes Wyeth commencing on the acquisition date of October 15, 2009.

^(b)	On November 30, 2011, Lipitor lost exclusivity in the U.S. This loss of exclusivity reduced revenues by $326 million in 2011, in comparison with 2010.

^(c)	Acquired from Wyeth.

^(d)	Represents direct sales under license agreement with Eisai Co., Ltd.

⁽^e⁾	Acquired from King.

^(f)	Enbrel (in the U.S. and Canada), Aricept, Exforge, Rebif and Spiriva.

⁽^g⁾	Includes products from legacy Pfizer, legacy Wyeth and legacy King.

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References+ Details